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SUMMARY
This perspective discusses some activities of mesenchymal stem cells (MSCs) in the context of angiogenesis, focusing on contrasting
effects that could call into question the extent to which MSCs can be used clinically in the future. We report on the antiangiogenic/
antiproliferative effects of specific MSC populations (including bone marrow MSCs), their paracrine activity, tissue heterogeneity,
and endothelial cell interactions. Also discussed are what could lead to contrasting effects of the influence of MSCs in regulating angio-
genesis, pointing to somenegativeeffects of these cells. In conclusion, this articlehighlights important aspects ofMSCbehaviorwithin the
perspective of translational medicine applications. STEM CELLS TRANSLATIONALMEDICINE 2016;5:1–4
SIGNIFICANCE
Multipotentmesenchymal stem cells (MSCs) can be extracted fromvirtually every organ and tissue in the body. Although they have
previously been shown to be an important source of blood vessel-attracting factors, useful for tissue repair and regenerative med-
icine, recent studies have found that specificMSC populations can also produce factors that inhibit blood vessel growth. Abnormal
vascularization is associated with the progression of many diseases, and identification of these unique blood vessel-inhibiting
MSCs has highlighted a potential source of cytotoxic factors that could be used to control pathological angiogenesis, for example,
tumors.
INTRODUCTION
Past research efforts describing thebeneficial effects ofmesenchy-
mal stem cells (MSCs) clinically originally focused upon theirmulti-
potency and capacity for self-renewal. However, today we now
know that MSCs also produce a broad spectrum of proangiogenic
factors that candirectly facilitate theproliferation andmigrationof
endothelial cells (ECs) and contribute to the recruitment of endo-
thelial progenitor cells [1]. As a consequence, MSCs may exert in-
direct benefits via the production of growth factors to positively
influence blood vessel infiltration and improve rates of tissue re-
generation and repair.
Advantageous effects of MSCs on vascular function have been
described widely in animal and clinical studies, including ischemia,
in which bone marrow (BM)-derived MSCs enhance limb perfu-
sion, increase blood vessel density, and improve overall limb func-
tion in amurinemodel [2]. Further evidence has demonstrated the
therapeutic benefits of BM [3], adipose [4], and pulp [5] MSCs in a
rat model of myocardial infarction in which MSC transplantation
significantly improved ventricular function and was associated
with increased angiogenesis. In stroke, the initial idea of MSC
transplantation was by the potential transdifferentiation of MSCs
into glial cells and neurons, but the beneficial effects actually ap-
pear to be a result of MSC-mediated enhancement of endogenous
angiogenesis [6]. Cotransplantation of murine kidney MSCs with
islets of Langerhans has been shown to significantly improve
clinical outcomes of diabeticmice by increasing islet graft revascu-
larization following transplantation [7]. Combination therapies of
MSCs and polymeric growth factor release scaffolds tailored to
promote angiogenesis and osteogenesis are also under evalua-
tion and development to actively stimulate bone regeneration
(reviewed by Kanczler and Oreffo [8]). MSCs are generally thought
to influence EC function by the paracrine production of proangio-
genic factors including vascular endothelial growth factor (VEGF),
hepatocyte growth factor, basic fibroblast growth factor, insulin-
like growth factor-1, transforming growth factor-b (TGF-b),
platelet-derived growth factor (PDGF), angiopoietin, interleukin-
6 (IL-6), and monocyte chemotactic protein-1. Exosomes released
byMSCs are also thought to influence angiogenesis by transferring
genetic materials and angiogenic molecules. ECs also have a re-
ciprocal capacity to modulate the behavior of mesenchymal cells,
for example, by the expression of growth promotors and inhibitors
suchaNotch [9].And there is accumulating evidence to suggest the
BM-MSCsmay also have promoting effects on hematopoietic stem
cells (HSCs) with engraftment and repopulation in several studies
demonstrating that cotransplantation of human MSCs and HSCs
results in increased hematopoietic recovery in animal models
and humans [10–12].
In contrast to the body of accumulated work detailing posi-
tive effects of MSCs on angiogenesis, several recent studies have
emerged that describe an apparent detrimental influence of MSCs
onECfunction. Suchcontrastingeffects couldquestion theextent to
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PERSPECTIVES
which MSCs could be used clinically, and the reported anti-
angiogenic effects of specific MSC populations will be the focus
of this Perspective.
ANTIANGIOGENIC ACTIONS OF BONE MARROW-DERIVED MSCS
Because of their accessibility, bone marrow (BM)-derived MSCs
areprobably thebest characterizedMSCpopulation and themost
commonly used MSC in clinical practice. One of the most heavily
researched areas with regard to effects of MSCs on vascular EC
function clinically is with reference to tumorigenesis. Contrasting
effects of the influence of MSCs in regulating angiogenesis have
been described in the context of tumor growth, which is unsur-
prising given the complexity of the disease, the broad cellular
heterogeneity of the tumor itself, and its reliance upon the vas-
culature. BM-MSCs have been shown to recruit ECs to induce an-
giogenesis in stable tissue [13] aswell as in tumors [14], raising the
possibility that MSCs may promote tumor growth. However, by
contrast, intravenously injected MSCs were found to abrogate
growth of the Kaposi sarcoma [15], suggesting that MSCs could
also possess cytotoxic properties.
A concentration-dependent inhibition of angiogenesis has
been reported in melanoma, with rat BM-MSCs. Using in vitro
capillary cultures, it was shown that addition of MSCs caused a
dose-dependent effect on EC cytotoxicity that was attributable
to MSC:EC gap junction communication and the production of
MSC-derived reactive oxygen species. The combined effect of
these responses resulted in capillary destruction. Furthermore,
in an in vivo melanoma model, the rat BM-MSCs inhibited tumor
growth by abrogating growth of the tumor vasculature, and these
results demonstrate a novel property of MSCs, namely, as cyto-
toxic agents that can inhibit the formation of capillary networks
[16]. Following on from this study, physiologically, the large num-
bers ofMSCs thatwould be required for such cytotoxic effects are
unlikely to be achieved in capillary beds with normal blood flow,
because thecells are likely tobe flushedaway.However, cytotoxic
effects might become evident to the extent that administered
MSCs aggregate in, for example, the reticulo-endothelial system,
such as in the liver and spleen.
A further example of the antiproliferative activity of human
MSCs on tumor cells of hematopoietic origin was reported by
Ramasamy et al., who showed that BM-MSC produced the tran-
sient arrest of tumor cells in the G1 phase of the cell cycle in
vitro [17]. A coinjection of tumor cells and BM-MSCs, however,
resulted in an increased incidence of tumor growth in immuno-
deficient mice. The authors concluded that the discrepancy
between the in vitro and in vivo findings would be due to de-
velopment of a cancer stem cell niche after cotransplantation
of MSC in which the tumorigenicity can be augmented [17]. Co-
administration of human BM-MSCs and glioma cells also sig-
nificantly reduced tumor size and vascular density, with MSCs
downregulating the expression of angiogenic molecules [18] in
glioma cells and BM-MSC glioma cocultures showing reduced ex-
pression of PDGF-B and IL-1b. It was proposed that theMSCsmay
exert their antitumor effect through the downregulation of the
PDGF/PDGFR axis, which is critical in the regulation of glioma an-
giogenesis. Tumor cells play a decisive role in mutual cross-talks
between the diverse heterogeneity of cell types in the tumor micro-
environment [19], suggesting thepossibility of dual, contradicting ef-
fects of MSCs in tumor neo-angiogenesis dependent on tumor
origin. For example, in contrast to the proangiogenic effects of
MSCs described in “normal” tissue, it appears evident in specific
tumor microenvironments that MSCs alter their production of
proangiogenic growth factors and mediators.
Outside of tumorigenesis, an antiangiogenic and anti-
inflammatory action of rat BM-MSC lines has also been described
in corneal wound healing [20]. Investigations were undertaken to
determine whether transplantation of MSCs could improve ocu-
lar surface reconstruction by modulating corneal inflammation
and angiogenesis in mice with a chemical burn. Surprisingly,
the authors described a rapid regression of new vessels in the
MSCorMSC-conditionedmedia group,whichwas consistentwith
other studies [21, 22]. To examine this further, the authors mea-
sured the expression of molecules known to be involved in cor-
neal angiogenesis and found an upregulation of antiangiogenic
thrombospondin-1 and downregulation of proangiogenic matrix
metalloproteinase.
TISSUE HETEROGENEITY AND ENDOTHELIAL CELL INTERACTIONS
To date, MSCs have now been successfully isolated from a num-
ber of other organs including brain, liver, kidney, lung, muscle,
thymus, pancreas, skin, lung umbilical cord, and placenta [23].
It has been proposed that the capacity tomodulate the formation
of the vasculature is a ubiquitous property of all MSCs, irrespec-
tive of their anatomical location. In one study,MSCswere isolated
from four murine tissues, including bone marrow, white adipose
tissue, skeletal muscle, and myocardium [24]. The authors de-
scribed that all four MSC populations secreted a plethora of
proangiogenic factors that induced proliferation, migration,
and tube formation of endothelial colony forming cells (ECFCs).
In vivo, coimplantation of these MSCs with ECFCs into mice gen-
erated an extensive network of blood vessels, with ECFCs spe-
cifically lining the lumens and MSCs occupying perivascular
positions. But importantly, the authors concluded that there were
no differences among all four different populations of MSCs
evaluated.
In contrast, others have described potent differences existing
betweenpopulations of tissuederived-MSCs and their capacity to
regulate the vasculature. Kern et al. compared the proliferative
capacity of MSCs isolated from BM, adipose tissue, and umbilical
cord, and analysis of BM-MSCs and umbilical cord veinMSCs that
followed showed that the former had higher expression levels of
genes associated with osteogenic differentiation, whereas the
latter exhibited a higher expression of genes involved in angio-
genesis [25]. Itwas alsodemonstrated that adipose-derivedMSCs
exhibit greater angiogenic potential in comparisonwithBM-MSCs
[26] and may be more effective in cardiovascular pathologies as-
sociated with ischemia.
Consistent with MSCs from different tissue sources exhibiting
unique behaviors, an endogenous population of MSCs present in
islets of Langerhans has recently been identified that exerts po-
tent detrimental effects onEC survival in vitro [27]. Upon isolation
and expansion, human islet MSCs expressed higher levels of
proangiogenic VEGF when compared with human BM-MSCs.
However, after coculture with human microvascular ECs, islet
MSCs exerted a rapid negative effect on EC viability, inducing
EC apoptosis both following direct cell:cell contact and via the
production of soluble mediators. When TGF-b signaling via
activin-like kinase-5 activity was inhibited during coculture, EC
survival was maintained, highlighting that MSC-derived growth
factors were responsible for this effect.
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SPATIAL INFLUENCE ON MSC-ANGIOGENIC POTENTIAL
Differential impacts of MSCs on EC function have also been
described within the same study using two-dimensional (2D)
and three-dimensional (3D) culture systems. In a 2D culture sys-
tem of ECs (human umbilical vein endothelial cells) and human
BM-MSCs, a cell count was performed, and after 9 days of co-
culture the number of viable ECs was significantly reduced in
the presence of MSCs. Monocultured ECs showed a typical
cobblestone-like morphology after 1 week’s 2D culture in vitro,
and with the addition of BM-MSCs a less proliferative phenotype
could be observed in which the ECs did not organize into micro-
vascular networks in thepresenceofMSCsat this ratio. In order to
determine the influence of BM-MSCs on EC quiescence, the ex-
pression of CD31 and vWFwas analyzed whereby in EC:MSC con-
structs, a downregulation of both markers was found after 1
week’s culture in vitro, as well as after 1 week’s in vivo implanta-
tion. In contrast, 3D cell/scaffold constructs induced a higher vas-
cular density than did control scaffolds, whereas the highest
density of capillaries was achieved through coseeding of ECs
and MSCs [28].
CONCLUSION
Although MSCs have previously been given much attention be-
cause of their positive effects upon EC growth and angiogenesis
in instances such as tissue transplantation or regeneration, it now
appears that communication with vasculature by MSCs is com-
plex and tissue specific. Evidence strongly supports a perivascular
origin for MSCs, and previous results have demonstrated that
MSCs can stabilize and maintain vascular structures in vivo
[29]. Indeed, a landmark publication has presented a large body
ofwork that defines and validates both the in situ and in vitro links
between MSCs and perivascular cells or pericytes [30]. An in-
creased understanding of the origin of MSCs and their contribu-
tion to blood vessel function as perivascular cells in vivo should
help clarify why MSCs appear to exert such differential effects
on EC function. Indeed, it is well established that in vivo the vas-
culature is highly heterogeneous, and the endothelium can
mold itself and its behavior to the functional requirements of
the underlying tissue. Thus, it is therefore entirely plausible that
pericytes and MSCs in vivo could exert similar levels of hetero-
geneity dependent on the function of the tissue in which they
exist.
Current evidence suggests thatMSCs can exert variable immu-
nomodulatory effects that are also dependent on the localmicro-
environment or disease status; for example, MSCs decrease the
Th1 response in patients with acute graft versus host disease
(GvHD) [31] and autoimmune diseases such as systemic lupus
erythematosus. Currently, it has not been established whether
putative antiangiogenic MSCs can exert immunomodulatory
properties or indeed influencehematopoiesis. But given thatneo-
vascularization plays a significant role in GvHD severity, for exam-
ple, there is potential that treatment with antiangiogenic MSC
populations could exert dual effects to both control pathological
vascularization and provide immunomodulation.
Theongoingdiscrepanciesdescribedbetween stemcell studies
could be due toMSCbehavior in vitro not accurately representing
their behavior in vivo. For example, BM-MSCs have been shown
in vivo to actually possess limited multipotency within bone,
with genetic pulse chase studies of osteolineage progenitors
demonstrating that in situ, BM-MSCs have a hierarchical organi-
zation serving to replace short-lived, postmitotic mature cells
[32]. These studies highlight that multipotency ex vivo should
Table 1. Summary of angiogenic versus antiangiogenic influence of mesenchymal stem cells extracted from different species and tissues
MSCs Experimental set-up In vitro In vivo Reference
Rat
Rat BM-MSC Melanoma Antiangiogenic Antiangiogenic In’t Anker et al. [12]
Corneal wound healing Antiangiogenic Antiangiogenic Otsu et al. [16]
Myocardial infarction Angiogenic Dai et al. [3]
Rat pulp Myocardial infarction Angiogenic Miyahara et al. [4]
Rat adipose Myocardial infarction Angiogenic Gandia et al. [5]
Human
Human BM-MSC Hematopoietic tumor cells Antiangiogenic Angiogenic Al-Khaldi et al. [13]
Glioma Antiangiogenic Antiangiogenic Annabi et al. [14]
2D culture Antiangiogenic Lin et al. [24]
3D culture Angiogenic Lin et al. [24]
Human islet MSC Islet transplantation Antiangiogenic Shah [23]
Mouse
Mouse BM-MSC Stroke Angiogenic Angiogenic Zhang and Chopp [6]
Ischemia Angiogenic Angiogenic Kinnaird et al. [2]
Endothelial colony cells Angiogenic Angiogenic Oh et al. [20]
Mouse adipose MSC Endothelial colony cells Angiogenic Angiogenic Oh et al. [20]
Mouse skeletal muscle MSC Endothelial colony cells Angiogenic Angiogenic Oh et al. [20]
Mouse myocardium MSC Endothelial colony cells Angiogenic Angiogenic Oh et al. [20]
Mouse kidney MSCs Islet transplantation Angiogenic Angiogenic Rackham et al. [7]
Abbreviations: BM, bone marrow; 2D, two dimensional; 3D, three dimensional; MSC, mesenchymal stem cell.
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be interpreted with caution and are unlikely to represent how
cells will function in vivo. Such observations should be extended
to in vitro studies of MSC interactions with ECs, not representing
how they interacted in vivo nor how they will behave if cultured
and transplanted. It is also likely that extraction techniques and
passage number used will be critical in disclosing any tissue-
specific differences present between MSC populations and their
communicationwith the vasculature. Details of passage numbers
and isolation techniques are frequently omitted frommanuscript
methodology, and oftenMSC populations are expanded contin-
uously and become homogeneous. The species fromwhichMSC
populations have originated may have some influence on the an-
giogenic potential of the cells, with humanMSCs appearing to ex-
ert the most antiangiogenic influence both in vitro and in vivo in
contrast tomouse-derivedMCS,which appear topromote consis-
tently proangiogenic effects (Table 1). This may also be linked to
the age of theMSCs in these studies, with humanMSCs generally
being extracted fromadult/aged tissue. Thus, direct comparison
between studies and between tissues remains problematic.
However, given that there has already been partial success in us-
ing MSCs in vivo to modulate angiogenesis, an improved under-
standing of MSC heterogeneity could further develop and
broaden their use clinically. With aberrant vascular function
central to many diseases, a capacity to control pathological an-
giogenesis using MSCs administered at certain densities, de-
rived from specific tissues or cultured under specific spatial
conditions, could provide exciting new opportunities to expand
the use of MSCs therapeutically.
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